Funder: Foundation for Women's Cancer
Due Dates: October 7, 2026 (LOI) | December 9, 2026 (Full proposal, invitation only)
Funding Amounts: $72,500 for one year
Summary: Supports research on early detection of ovarian cancer, premalignant lesions, and biomarkers for ovarian cancer or recurrence.
Key Information: Research must take place at a U.S. institution; non-SGO members need an SGO co-investigator or sponsor.
Description
The Amy Krouse Rosenthal Foundation grant is offered through the Foundation for Women’s Cancer (FWC) as part of its 2026–2027 Ovarian Cancer Grants category. It supports research into ovarian cancer early detection and recurrence biomarker development, with priority given to early career professionals and junior investigators.
Projects must address either early detection of premalignant lesions or biomarker development for detecting ovarian cancer or recurrence. Premalignant-lesion research may include serous tubal intraepithelial carcinoma (STIC), using serum/plasma analysis, uterine lavage, Pap smears, or fallopian tube sampling. Biomarker research may include identifying high-risk patients, such as BRCA or PALB2 mutation carriers, developing early detection methods within these populations, and studying the biology of premalignant lesions and early ovarian cancer.
